Connecticut Wealth Management LLC Has $403,000 Position in AstraZeneca PLC (NASDAQ:AZN)

Connecticut Wealth Management LLC grew its position in AstraZeneca PLC (NASDAQ:AZN) by 78.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,984 shares of the company’s stock after purchasing an additional 2,638 shares during the period. Connecticut Wealth Management LLC’s holdings in AstraZeneca were worth $403,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Clearstead Advisors LLC increased its position in AstraZeneca by 15.5% in the third quarter. Clearstead Advisors LLC now owns 1,209 shares of the company’s stock worth $82,000 after purchasing an additional 162 shares during the period. Bryn Mawr Capital Management LLC raised its stake in shares of AstraZeneca by 0.3% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 61,866 shares of the company’s stock worth $4,167,000 after buying an additional 164 shares during the last quarter. Gradient Investments LLC lifted its holdings in AstraZeneca by 2.4% in the third quarter. Gradient Investments LLC now owns 7,259 shares of the company’s stock valued at $492,000 after buying an additional 169 shares during the period. Drive Wealth Management LLC boosted its stake in AstraZeneca by 4.5% in the fourth quarter. Drive Wealth Management LLC now owns 3,911 shares of the company’s stock valued at $263,000 after acquiring an additional 170 shares during the last quarter. Finally, Glenview Trust co grew its holdings in AstraZeneca by 3.8% during the 3rd quarter. Glenview Trust co now owns 4,724 shares of the company’s stock worth $320,000 after acquiring an additional 174 shares during the period. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Down 0.8 %

Shares of AZN stock traded down $0.58 during trading on Monday, reaching $75.77. The company’s stock had a trading volume of 3,291,708 shares, compared to its average volume of 6,329,115. The company has a market cap of $234.92 billion, a price-to-earnings ratio of 37.43, a price-to-earnings-growth ratio of 1.39 and a beta of 0.47. AstraZeneca PLC has a one year low of $60.47 and a one year high of $76.80. The business has a fifty day moving average price of $68.38 and a 200-day moving average price of $66.34. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.73 earnings per share for the quarter, missing the consensus estimate of $0.74 by ($0.01). AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. The company had revenue of $12.02 billion during the quarter, compared to the consensus estimate of $12.07 billion. During the same quarter in the previous year, the business earned $0.69 EPS. AstraZeneca’s revenue was up 7.3% on a year-over-year basis. Analysts anticipate that AstraZeneca PLC will post 4.01 earnings per share for the current year.

AstraZeneca Increases Dividend

The company also recently announced a Semi-Annual dividend, which was paid on Monday, March 25th. Stockholders of record on Friday, February 23rd were paid a dividend of $0.965 per share. The ex-dividend date was Thursday, February 22nd. This represents a dividend yield of 2.3%. This is a positive change from AstraZeneca’s previous Semi-Annual dividend of $0.47. AstraZeneca’s dividend payout ratio (DPR) is 94.61%.

Analysts Set New Price Targets

AZN has been the topic of a number of analyst reports. Morgan Stanley started coverage on AstraZeneca in a research note on Tuesday, January 23rd. They issued an “overweight” rating on the stock. BMO Capital Markets lifted their price objective on shares of AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, April 26th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, April 16th. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $81.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.